1. Home
  2. STKH vs ENTO Comparison

STKH vs ENTO Comparison

Compare STKH & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STKH
  • ENTO
  • Stock Information
  • Founded
  • STKH 2018
  • ENTO 2014
  • Country
  • STKH Israel
  • ENTO United States
  • Employees
  • STKH N/A
  • ENTO N/A
  • Industry
  • STKH Packaged Foods
  • ENTO Biotechnology: Pharmaceutical Preparations
  • Sector
  • STKH Consumer Staples
  • ENTO Health Care
  • Exchange
  • STKH Nasdaq
  • ENTO Nasdaq
  • Market Cap
  • STKH 1.6M
  • ENTO 1.9M
  • IPO Year
  • STKH 2021
  • ENTO 2016
  • Fundamental
  • Price
  • STKH $1.38
  • ENTO $0.47
  • Analyst Decision
  • STKH
  • ENTO
  • Analyst Count
  • STKH 0
  • ENTO 0
  • Target Price
  • STKH N/A
  • ENTO N/A
  • AVG Volume (30 Days)
  • STKH 3.0M
  • ENTO 1.6M
  • Earning Date
  • STKH 08-29-2025
  • ENTO 05-15-2025
  • Dividend Yield
  • STKH N/A
  • ENTO N/A
  • EPS Growth
  • STKH N/A
  • ENTO N/A
  • EPS
  • STKH N/A
  • ENTO N/A
  • Revenue
  • STKH $10,000.00
  • ENTO N/A
  • Revenue This Year
  • STKH N/A
  • ENTO N/A
  • Revenue Next Year
  • STKH N/A
  • ENTO N/A
  • P/E Ratio
  • STKH N/A
  • ENTO N/A
  • Revenue Growth
  • STKH N/A
  • ENTO N/A
  • 52 Week Low
  • STKH $1.33
  • ENTO $0.19
  • 52 Week High
  • STKH $17.71
  • ENTO $1.11
  • Technical
  • Relative Strength Index (RSI)
  • STKH 41.54
  • ENTO 51.42
  • Support Level
  • STKH $1.41
  • ENTO $0.44
  • Resistance Level
  • STKH $3.59
  • ENTO $0.51
  • Average True Range (ATR)
  • STKH 0.22
  • ENTO 0.05
  • MACD
  • STKH -0.00
  • ENTO 0.00
  • Stochastic Oscillator
  • STKH 1.83
  • ENTO 53.27

About STKH Steakholder Foods Ltd.

Steakholder Foods Ltd is engaged in transforming the alternative protein industries through its technology. The group specializes in developing and selling 3D-printing production machines, supported by proprietary premix blends, formulated from the highest-quality raw ingredients. These tools help manufacturers of all sizes efficiently produce foods that meet consumer expectations for taste, texture, and appearance and offer a safe and sustainable alternative to industrialized meat and seafood production. The company's expertise in creating alternative protein products replicating traditional meats' complex textures such as beef steaks, white fish, shrimp, and eel. It also explores the integration of cultivated cells, preparing for future advancements in food technology.

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: